JTC Employer Solutions Trustee’s BioMarin Pharmaceuticals BMRN Stock Holding History

JTC Employer Solutions Trustee’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-567	Closed	-$40K	–	324
2024 Q3	$40K	Hold	567	–	–	﹤0.01%	255
2024 Q2	$47K	Hold	567	–	–	﹤0.01%	251
2024 Q1	$50K	Hold	567	–	–	﹤0.01%	255
2023 Q4	$55K	Hold	567	–	–	0.01%	244
2023 Q3	$50K	Hold	567	–	–	﹤0.01%	252
2023 Q2	$49K	Hold	567	–	–	﹤0.01%	262
2023 Q1	$55K	Hold	567	–	–	0.01%	256
2022 Q4	$59K	Hold	567	–	–	0.01%	249
2022 Q3	$48K	Hold	567	–	–	0.01%	213
2022 Q2	$47K	Hold	567	–	–	0.01%	194
2022 Q1	$44K	Hold	567	–	–	﹤0.01%	217
2021 Q4	$50K	Hold	567	–	–	0.01%	215
2021 Q3	$44K	Hold	567	–	–	0.01%	223
2021 Q2	$47K	Buy	+567	New	+$44.9K	0.01%	216

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

JTC Employer Solutions Trustee's BMRN Position: Q4 2024 in Review

JTC Employer Solutions Trustee sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 567 shares — an estimated $40K sold.

JTC Employer Solutions Trustee first reported a position in BMRN in Q2 2021 and held it in 14 quarters. The position peaked at $59K in Q4 2022. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

JTC Employer Solutions Trustee reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
JTC Employer Solutions Trustee sold 567 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $40K.
JTC Employer Solutions Trustee first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 14 quarters.
JTC Employer Solutions Trustee's BioMarin Pharmaceuticals position peaked at $59K in Q4 2022.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on JTC Employer Solutions Trustee's 13F filing for Q4 2024, filed 13 Jan 2025.